PMID- 18674550
OWN - NLM
STAT- MEDLINE
DCOM- 20090126
LR  - 20211020
IS  - 0028-3908 (Print)
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 55
IP  - 7
DP  - 2008 Dec
TI  - (+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path 
      integration learning: a comparison of single vs once per week treatment for 5 
      weeks.
PG  - 1121-30
LID - 10.1016/j.neuropharm.2008.07.006 [doi]
AB  - 3,4-Methlylenedioxymethamphetamine (MDMA) administration (4 x 15 mg/kg) on a 
      single day has been shown to cause path integration deficits in rats. While most 
      animal experiments focus on single binge-type models of MDMA use, many MDMA users 
      take the drug on a recurring basis. The purpose of this study was to compare the 
      effects of repeated single-day treatments with MDMA (4 x 15 mg/kg) once weekly 
      for 5 weeks to animals that only received MDMA on week 5 and saline on weeks 1-4. 
      In animals treated with MDMA for 5 weeks, there was an increase in time spent in 
      the open area of the elevated zero maze suggesting a decrease in anxiety or 
      increase in impulsivity compared to the animals given MDMA for 1 week and saline 
      treated controls. Regardless of dosing regimen, MDMA treatment produced path 
      integration deficits as evidenced by an increase in latency to find the goal in 
      the Cincinnati water maze. Animals treated with MDMA also showed a transient 
      hypoactivity that was not present when the animals were re-tested at the end of 
      cognitive testing. In addition, both MDMA-treated groups showed comparable 
      hyperactive responses to a later methamphetamine challenge. No differences were 
      observed in spatial learning in the Morris water maze during acquisition or 
      reversal but MDMA-related deficits were seen on reduced platform-size trials. 
      Taken together, the data show that a single-day regimen of MDMA induces deficits 
      similar to that of multiple weekly treatments.
FAU - Skelton, Matthew R
AU  - Skelton MR
AD  - Division of Neurology, Cincinnati Children's Research Foundation and University 
      of Cincinnati College of Medicine, Cincinnati, OH 45229-3039, USA.
FAU - Able, Jessica A
AU  - Able JA
FAU - Grace, Curtis E
AU  - Grace CE
FAU - Herring, Nicole R
AU  - Herring NR
FAU - Schaefer, Tori L
AU  - Schaefer TL
FAU - Gudelsky, Gary A
AU  - Gudelsky GA
FAU - Vorhees, Charles V
AU  - Vorhees CV
FAU - Williams, Michael T
AU  - Williams MT
LA  - eng
GR  - K01 DA014269-05/DA/NIDA NIH HHS/United States
GR  - R01 DA006733-16/DA/NIDA NIH HHS/United States
GR  - DA006733/DA/NIDA NIH HHS/United States
GR  - K01 DA014269/DA/NIDA NIH HHS/United States
GR  - R01 DA007427-14/DA/NIDA NIH HHS/United States
GR  - T32 ES007051-32/ES/NIEHS NIH HHS/United States
GR  - T32 ES007051/ES/NIEHS NIH HHS/United States
GR  - ES007051/ES/NIEHS NIH HHS/United States
GR  - DA007427/DA/NIDA NIH HHS/United States
GR  - R01 DA006733/DA/NIDA NIH HHS/United States
GR  - DA014269/DA/NIDA NIH HHS/United States
GR  - R01 DA007427/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080712
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Hallucinogens)
RN  - 0 (Neurotransmitter Agents)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Anxiety/psychology
MH  - Behavior, Animal/drug effects
MH  - Body Temperature/drug effects
MH  - Body Weight/drug effects
MH  - Hallucinogens/*pharmacology
MH  - Learning/*drug effects
MH  - Male
MH  - Maze Learning/drug effects
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Neurotransmitter Agents/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Recognition, Psychology/drug effects
MH  - Swimming/psychology
MH  - Time Factors
PMC - PMC2703563
MID - NIHMS79695
EDAT- 2008/08/05 09:00
MHDA- 2009/01/27 09:00
PMCR- 2009/12/01
CRDT- 2008/08/05 09:00
PHST- 2007/12/14 00:00 [received]
PHST- 2008/06/25 00:00 [revised]
PHST- 2008/07/04 00:00 [accepted]
PHST- 2008/08/05 09:00 [pubmed]
PHST- 2009/01/27 09:00 [medline]
PHST- 2008/08/05 09:00 [entrez]
PHST- 2009/12/01 00:00 [pmc-release]
AID - S0028-3908(08)00279-7 [pii]
AID - 10.1016/j.neuropharm.2008.07.006 [doi]
PST - ppublish
SO  - Neuropharmacology. 2008 Dec;55(7):1121-30. doi: 10.1016/j.neuropharm.2008.07.006. 
      Epub 2008 Jul 12.